Orca Bio
Orca Bio is a late-stage biotechnology company developing next-generation cell therapies to improve transplant outcomes. The Material Handler at the Sacramento manufacturing facility supports the delivery and storage of pharmaceutical materials and products that enable cell therapy production. This on-site, third-shift role contributes to maintaining product quality and regulatory compliance.
Headquarters
Menlo Park, California, United States
Company Size
51-200 employees
Founded
2016
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. The company's investigational allogeneic T-cell immunotherapies harness the power of regulatory T cells with the goal of providing better patient outcomes with fewer risks. Orca Bio is committed to delivering the promise of cell therapy to patients without compromise through its high-precision technology and manufacturing approach.
Orca Bio Announces $250M in Aggregate Financing in Preparation for Potential Commercialization
Jan 9, 2026
Orca Bio’s BLA for Hematologic Malignancy Cell Therapy Orca-T Accepted by FDA With Priority Review
Oct 7, 2025
Orca Bio Presents New Clinical Data on its Pipeline of High-Precision Cell Therapies including Orca-Q® Without GvHD Prophylaxis and Orca-T/CAR-T Combination Therapy at the 67th ASH Annual Meeting
Dec 9, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Orca Bio.
Orca Bio didn’t post a salary, so this is our estimate from similar listings.
Orca Bio, with labs in Sacramento, raises $250 million to commercialize blood cancer treatment
Jan 12, 2026